# A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

> **NCT03802695** · PHASE1 · RECRUITING · sponsor: **Orca Biosystems, Inc.** · enrollment: 300 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Mixed Phenotype Acute Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** OrcaGraft (Orca-Q)

## Key facts

- **NCT ID:** NCT03802695
- **Lead sponsor:** Orca Biosystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-08
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03802695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03802695, "A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03802695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*